thiazolidines has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, PH; Cho, YH; Choi, KY; Kim, JY; Lee, JD; Paik, S; Park, JC; Ryu, WJ; Sohn, JH | 1 |
| Cai, Y; Yao, D; Zheng, Q; Zhou, T | 1 |
| Haroun, M; Helmy, MW; Moussa, N; Nasser, F | 1 |
| Brasó-Maristany, F; Buus, R; Castel, P; Catchpole, S; Cheang, MC; Filosto, S; Francesch-Domenech, E; Gazinska, P; Grigoriadis, A; Gris-Oliver, A; Liccardi, G; Marlow, R; Marra, P; Mathew, S; McEachern, K; Meier, P; Noël, E; Noor, F; Patel, N; Perdrix-Rosell, A; Plumb, DA; Quist, J; Scaltriti, M; Serra, V; Shafat, M; Tutt, AN; Watkins, J; Zakka, L | 1 |
4 other study(ies) available for thiazolidines and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Protein Stability; ras Proteins; Thiazolidines; Triple Negative Breast Neoplasms; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2020 |
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammasomes; Interleukin-1beta; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Thiazolidines; Thiones; Triple Negative Breast Neoplasms; Up-Regulation; Wnt Signaling Pathway | 2020 |
Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Interactions; Humans; Pyrimidinones; Receptor, Notch1; Thiazolidines; Transcription Factor HES-1; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2021 |
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Copy Number Variations; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-pim-1; Real-Time Polymerase Chain Reaction; Thiazolidines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2016 |